Federal Contractor Misconduct Database (FCMD)
In re Wellbutrin Direct Purchaser Antitrust Litigation
A class action antitrust suit accused GlaxoSmithKline of using monopolistic tactics against generic drug manufacturers to boost profits from its antidepressant drug Wellbutrin. The plaintiffs, direct purchasers of the drug, claimed that GSK devised a plan to keep Wellbutrin prices high by making fraudulent assertions to the U.S. Patent and Trademark Office and by engaging in sham patent litigation against generic drug manufacturers to keep a generic version of Wellbutrin from coming to market. In 2011, GSK agreed to settle the lawsuit for $49 million (plus up to $500,000 to cover the costs of notifying the class and administering the settlement).
- Misconduct Type
- Enforcement Agency
- Contracting Party
- Court Type
- Date of Class Certification